Retatrutide
Contact Us →Retatrutide (also known as LY3437943) is a triple agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR). It has attracted growing interest in research focused on metabolic health, weight management, and glucose homeostasis.
Studies have shown that Retatrutide activates GIP, GLP-1, and glucagon signaling pathways, leading to enhanced energy expenditure, improved appetite suppression, increased lipid oxidation, and superior glycemic control compared to dual agonists. It may also play a role in hepatic steatosis reduction, cardiovascular risk improvement, and sustained weight loss.
Key Research Areas:
-
Triple GIP/GLP-1/GCGR agonism and metabolic regulation
-
Body weight reduction and obesity treatment
-
Glucose homeostasis and type 2 diabetes management
-
Hepatic fat resolution and NAFLD/NASH research
-
Energy expenditure and lipid metabolism
